FISHing for the Miracle of Eicosapentaenoic Acid
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Bhatt et al. report in the Journal the results of the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), in which 8179 high-risk patients who had elevated triglyceride levels and had been receiving statin therapy were randomly assigned to receive 2 g of icosapent ethyl twice daily or placebo containing mineral oil.1 The patients were enrolled mostly on the basis of secondary prevention (71%), and almost 60% had diabetes. At baseline, low-density lipoprotein (LDL) cholesterol levels were well controlled among the patients (median value, 75.0 mg per deciliter [1.94 mmol per liter]), and triglyceride levels were slightly elevated (median . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“experts in both regulatory agencies in the USA and the European Union (EU)—from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—approved highly purified EPA, icosapent ethyl, for cardiovascular prevention in patients with dyslipidaemia.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [112]
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5205 · Cited by 632
Prevention of Sudden Cardiac Death by Dietary Pure ω-3 Polyunsaturated Fatty Acids in Dogs
Billman, G. E., Kang, J. X., & Leaf, A. (1999) · Circulation · doi:10.1161/01.cir.99.18.2452 · Cited by 393
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358
Self-citationBallantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342
Self-citationZhang, M. J., & Spite, M. (2012) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071811-150726 · Cited by 171
Cited by
Djuricic, I., & Calder, P. C. (2021) · Nutrients · doi:10.3390/nu13072421 · Cited by 1,015
“DHA increases HDL-choles- 600 terol, especially the HDL2 subfraction which is cardioprotective, but EPA does not affect 601 HDL-cholesterol [192].”
BackgroundInfluentialAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
“Modeling of the predicted CVD effects of observed plasma lipid and CRP changes resulting from administration of mineral oil or EPA suggests that a considerable part of the apparent CVD benefit in REDUCE-IT was related to adverse effects of mineral oil in the control group, while about 13% of the CVD benefit was relate…”
BackgroundEstablished and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“Although there has been significant public debate surrounding the comparator used in the REDUCE-IT trial (mineral oil) [112, 113], experts in both regulatory agencies in the USA and the European Union (EU)—from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—approved highly purified E…”
BackgroundOrringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.014 · Cited by 103
“However, as described in an editorial that accompanied the REDUCE-IT paper, based on the modest changes from baseline with the mineral oil placebo in lipids and other risk markers, such as hs-CRP, it appears unlikely that adverse effects of the placebo control can explain more than a small fraction of the observed ben…”
MethodMineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103
“However, a few critics have suggested that the observed reduction in CV risk was not only due to positive effects of IPE but also due to negative effects from the pharmaceutical-grade mineral oil control, a supposition based on small elevations in some lipid levels and inflammatory markers in the placebo arm.(20) The…”
Background
Metadata
- Authors
- Kastelein, J. J. P., & Stroes, E. S. G.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 89-90
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2901156820
- Cited by
- 74
- References
- 10
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 9 · 2022: 10 · 2021: 12 · 2020: 17 · 2019: 17
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- icosapent ethyl, eicosapentaenoic acid, REDUCE-IT trial, cardiovascular events, triglyceride elevation, statin therapy, secondary prevention, diabetes mellitus, LDL cholesterol, omega-3 fatty acids
- MeSH terms
- Cardiovascular Diseases, Humans, Risk Factors, Eicosapentaenoic Acid, Hypertriglyceridemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FISHing for the Miracle of Eicosapentaenoic Acid. https://app.cochat.ai/papers/10.1056/nejme1814004
- The paper
- Kastelein, J. J. P., & Stroes, E. S. G. (2019). FISHing for the Miracle of Eicosapentaenoic Acid. New England Journal of Medicine. https://doi.org/10.1056/nejme1814004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.